Trial · NCT00848744
Comparison of Two Salicylic Acid Formulations
NCT00848744, Not applicable, Completed, Northwestern University; results first posted 2010-07-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Two Salicylic Acid Formulations. Trials, record NCT00848744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00848744
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Two Salicylic Acid Formulations
- NCT number
- NCT00848744
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 10 participants, actual
- Lead sponsor
- Northwestern University
- Conditions
- Acne Vulgaris
- Interventions
- Formulation A, Formulation B
- First posted
- 2009-02-20
- Last updated
- 2018-03-01
- Results first posted
- 2010-07-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Physician Global Assessment | 28 days; The visits include baseline, Day 2, Day 7 (+/- 1) and Day 28 (+/- 3). | Difference in physician global assessment between two formulations. We remain blinded as to which formulation, both containing salicylic acid, worked better on patients. Measure is a scale (not an option below). Best was 0 (clear), worst was 4 (severe). |
| Secondary | The Subject's Medication Side Effect Profile Will be Assessed Using a Application Site Scale for Dryness, Scaling, Redness, and Stinging/Burning. | 4 Weeks |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Physician Global Assessment | 28 days; The visits include baseline, Day 2, Day 7 (+/- 1) and Day 28 (+/- 3). | Analysis was per protocol. Each subject received formulations A and B randomized to opposite sides of the face. | units on a scale | MEAN |
| SECONDARY | The Subject's Medication Side Effect Profile Will be Assessed Using a Application Site Scale for Dryness, Scaling, Redness, and Stinging/Burning. | 4 Weeks | Data were not collected. |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Physician Global Assessment | Salicylic Acid | Baseline | 2.65 | Standard Deviation 0.41 | units on a scale |
| Physician Global Assessment | Formulation B | Baseline | 2.6 | Standard Deviation 0.52 | units on a scale |
| Physician Global Assessment | Salicylic Acid | Day 2 | 2.55 | Standard Deviation 0.44 | units on a scale |
| Physician Global Assessment | Formulation B | Day 2 | 2.45 | Standard Deviation 0.55 | units on a scale |
| Physician Global Assessment | Salicylic Acid | Day 7 | 2.4 | Standard Deviation 0.61 | units on a scale |
| Physician Global Assessment | Formulation B | Day 7 | 2.3 | Standard Deviation 0.59 | units on a scale |
| Physician Global Assessment | Salicylic Acid | Day 28 | 2.20 | Standard Deviation 0.63 | units on a scale |
| Physician Global Assessment | Formulation B | Day 28 | 2.15 | Standard Deviation 0.58 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Salicylic Acid | 10 | |
| Overall Study | COMPLETED | Salicylic Acid | 10 | |
| Overall Study | NOT COMPLETED | Salicylic Acid | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | irritation and swelling of face | Skin and subcutaneous tissue disorders | Salicylic Acid | 1 | 10 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Salicylic Acid | ||
| Total, other adverse events | Salicylic Acid | 1 | 10 |
| Total, serious adverse events | Salicylic Acid | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00848744
GET https://conductscience.org/api/trials/v1/NCT00848744/registered